Skip to content

Generate Biomedicines

US · GENB #2875 by market cap Listed 2026
9.54 -0.83 -8.00%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:32

Price chart

Pre-market 10.09 -2.70%
After-hours 9.90 +3.77%
Overnight 10.20 -1.64%
20.389.549.542026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on GENB?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bearish
  • Recent price momentum is -40.3% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 7.1% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days C → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 02:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall D

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability F

How much profit the business keeps from each dollar of sales and capital.

Operating margin -737.0% Better than 3%
Net margin -782.4% Better than 3%
Momentum D

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -40.8% Better than 10%
6-month return -34.3% Better than 15%
Distance below 52-week high 57.9% Better than 12%
Financial Health C

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 2.9x Better than 71%
Debt to assets 20.8% Better than 55%
Interest coverage -195.1x Better than 4%
Analyst View A+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 172.5% Better than 92%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -20.96%
1M -26.05%
3M -40.34%
6M -26.73%

Key statistics

Price & volume

Prev close
10.37
Open
10.06
Day range
9.40 - 10.58
Avg price
9.82
Volume
967.86K
Turnover
9.50M
Amplitude
11.38%
52-week range
9.40 - 22.67

Valuation

P/E
-4.87
P/E (TTM)
-5.03
P/B
3.23
EPS
-1.96
Net profit
-252.77M
Net assets
381.09M

Share structure

Market cap
1.23B
Float cap
576.68M
Shares out
129.10M
Float shares
60.45M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2026-02-27
52-week range 1% of range
9.40 22.67

57.9% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-8.65M net over the window

Short interest

Shares short
9.08M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Generate Biomedicines (GENB)?

Generate Biomedicines last traded at 9.54. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Generate Biomedicines's market cap?

About 1.23B.

What is the P/E ratio of Generate Biomedicines?

The trailing twelve-month P/E is -5.03. The Valuation tab shows it against the stock's own five-year range.

Does Generate Biomedicines pay a dividend?

Generate Biomedicines does not currently pay a regular dividend.

Is Generate Biomedicines a buy according to analysts?

The consensus of 3 analysts is a Buy rating, with an average 12-month price target of 26.00, which implies 172.5% upside from the current price. This is not investment advice.

What is Generate Biomedicines's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Generate Biomedicines a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 19:32:29 · For reference only, not investment advice and not tailored to your situation.

Generate Biomedicines discussion 0 comments

Add a comment